Skip to content
2000
Volume 18, Issue 2
  • ISSN: 2211-3525
  • E-ISSN: 2211-3533

Abstract

Background: With the goal of developing Alzheimer's disease therapeutics, we have designed and synthesized novel piperidone fused dipeptide (DPPS) derivatives possessing dual action such as acetylcholinesterase (AChE) and beta-amyloid peptide (Aβ) aggregation inhibition. Designed peptide was synthesized by solid phase peptide synthesis using FMOC chemistry protocol and characterized by mass spectroscopy. Methods: The amino acid sequence in peptide was analyzed by LC-MS-MS. In silico docking analysis was carried out using GLIDE software. The docking score using GLIDE was found to be -7.88 against AChE and -9.74 against BACE1 enzyme. In vitro enzyme inhibition assay was carried out for AChE enzyme and BACE1 enzyme. Results: The IC50 values of AChE inhibition and BACE1 of DPPS were found to be 0.4796 μM/ml and 0.0154 μM/ml, respectively. The correlation of in silico and in vitro results showed that DPPS possessed a greater ability to inhibit BACE1 enzyme.

Loading

Article metrics loading...

/content/journals/aia/10.2174/2211352517666190405155505
2020-06-01
2025-09-14
Loading full text...

Full text loading...

/content/journals/aia/10.2174/2211352517666190405155505
Loading

  • Article Type:
    Research Article
Keyword(s): AChE; Alzheimers disease; BACE1; DPPS; enzyme inhibition; peptides
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test